UTHR vs. ZTS: United Therapeutics vs. Zoetis Stock Comparison

November 11, 2026

How do United Therapeutics (UTHR) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

United Therapeutics (UTHR) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but UTHR is classified in Biotechnology while ZTS is classified in Pharmaceuticals.

Company profile comparison for United Therapeutics (UTHR) and Zoetis (ZTS)
Profile Item	UTHR	ZTS
Name	United Therapeutics Corporation	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	23.94 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 17, 1999	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

UTHR

ZTS

GSPC

United Therapeutics (UTHR) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for United Therapeutics (UTHR) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for United Therapeutics (UTHR) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Total Return (1Y)	28.77%	-30.10%
Total Return (3Y, Annualized)	37.63%	-20.42%
Total Return (5Y, Annualized)	23.78%	-16.87%

Risk Profile

Drawdown History

UTHR

ZTS

GSPC

United Therapeutics (UTHR) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for United Therapeutics (UTHR) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Volatility (1Y, Annualized)	35.00%	38.23%
Beta (5Y)	0.49	0.66
Max Drawdown (5Y)	-33.00%	-70.45%
Avg. Volume (3M)	694.55K	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

UTHR and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Sharpe Ratio (1Y)	0.70	-0.90
Sortino Ratio (1Y)	1.29	-1.10

Profitability

ROE (TTM)

Both United Therapeutics (UTHR) at 19.13% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both United Therapeutics (UTHR) at 38.61% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both United Therapeutics (UTHR) at 28.99% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
ROE (TTM)	19.13%	57.63%
ROA (TTM)	10.91%	14.87%
Net Margin (TTM)	38.61%	26.41%
Operating Margin (TTM)	28.99%	38.19%
Gross Margin (TTM)	86.34%	71.65%

Growth

Revenue Growth

Both United Therapeutics (UTHR) at 10.61% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both United Therapeutics (UTHR) at 13.07% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Revenue Growth (YoY)	10.61%	2.28%
Revenue Growth (3Y CAGR)	18.02%	5.42%
EPS Growth (YoY)	13.07%	10.05%
EPS Growth (3Y CAGR)	22.92%	10.27%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Zoetis (ZTS) carries debt-to-equity ratio of 2.80 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

United Therapeutics (UTHR) vs. Zoetis (ZTS): UTHR does not report debt-to-equity ratio, so it has no value marker; ZTS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Current Ratio (MRQ)	4.61	2.35
Debt / Equity (MRQ)	--	2.80
Net Debt / EBITDA	-1.53	1.92

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

Both United Therapeutics (UTHR) at 21.22 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both United Therapeutics (UTHR) at 7.51 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

United Therapeutics (UTHR) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for United Therapeutics (UTHR) and Zoetis (ZTS)
Metric	UTHR	ZTS
P/E Ratio (TTM)	21.22	13.50
P/S Ratio (TTM)	7.51	3.40
P/B Ratio (MRQ)	3.80	9.80
Free Cash Flow Yield (TTM)	1.90%	6.36%